Gene Detection Market

Rise in Cancer Testing to Drive Gene Detection Market Growth

The Gene Detection Market is valued at USD 12.7 Bn in 2026 and is projected to reach USD 35.9 Bn, growing at a CAGR of 16% by 2033. Use of gene detection in cancer testing is likely to spearhead in the coming years. Various gene detection methods are available to diagnose mutations and variants in DNA sequence that could result in excessive growth of cells consequently increasing the possibility of tumor growth. For example, various methods such as CHEK2 (for colorectal and breast cancer), RAD51D and BRIP1 (for ovarian cancer) and PALB2 (for pancreatic cancer) are available. In addition, rising cancer cases worldwide have prompted individuals to carry out preventive diagnosis and adopt personalized medicine. In turn, rising awareness among people is expected to drive demand for gene detection services. According to Global Cancer Observatory, cancer incidences worldwide were 19,292,789 in 2020 of which 9,958,133 deaths were observed. As per IARC (International Agency for Research on Cancer) analysis, new cancer incidences are likely to touch 30 million by end of 2040. With efficient gene detection, it will become possible to get information on cancer possibility in household and risk of development of new cancers in the coming years in the family. Moreover, for patients who are non-responsive to chemotherapy, gene detection can help in identifying presence of mutations in cancer cells that are therapy resistant. Using this information, cancer treating facilities can provide apt therapies to kill tumor cells. In addition, growing technological advances have further influenced adoption of gene detection in testing cancer. In December 2020, Roche introduced Cobas PIK3CA, a mutation test that can detect PIK3CA mutations in people suffering from metastatic or advanced breast cancer. In this backdrop, demand for cancer testing is expected to drive the growth of the gene detection market.

Prevalence of Autoimmune Diseases to Call for Efficient Gene Detection Methods

Gradual increase in the occurrence of autoimmune diseases continues to fuel demand for gene detection. Using gene detection, patients and clinicians are able to identify and categorize various hereditary factors that can potentially result in occurrence of an autoimmune disease. Till date, scientists have identified eighty autoimmune diseases. According to NSCF (National Stem Cell Foundation), around 4% of the global population suffers from one or more of these 80, with most common ones being type 1 diabetes, rheumatoid arthritis, multiple sclerosis, scleroderma, Crohn’s disease, lupus and psoriasis. Being one of the causes of chronic illness, prevalence of autoimmune diseases continues to demand for efficient gene detection tests and services. Against this backdrop, companies are developing advanced methods for gene detection, such as sequencing and RT-PCR, which is expected to bolster growth of the gene detection market in the years to follow.

Rising COVID 19 Cases to Impact Gene Detection Market

COVID 19 pandemic has triggered an increase in production of genetic test kits. Increasing number of COVID cases has raised safety concerns among individuals in hospitals and other healthcare facilities, due to which healthcare facilities are including additional shifts to scale up COVID 19/ SARS CoV 2 tests. For instance, AvellinoCoV2, a rapid gene detection test facilitates diagnosing of COVID 19 by carrying out identification and isolation of genetic markers as approved by CDC and FDA. Concerns regarding rising COVID 19 cases continues to influence demand for advanced diagnostics and methods, in turn impacting the gene detection market.

North America to Remain at the Vanguard of Growth in Gene Detection Market

Growing demand for gene detection in analyzing ancestry related problems is expected to fuel market’s growth in North America. Moreover, high prevalence of autoimmune diseases in emerging economies is triggering adoption of advanced gene detection methods and kits. For instance, according to NIH (National Institute of Environmental Health Sciences), autoimmune diseases affect around 24 million individuals in the United States. Moreover, NIH reveals that autoimmune diseases affect 5%-8% of the population in the US, and the rate is expected to further increase. As per AARDA (American Autoimmune Related Diseases Association), cost associated with treatment of autoimmune diseases is around US$ 86 billion every year. This has propelled use of gene detection kits in an attempt to lower autoimmune incidences and expenditure. Also, growing product approvals by FDA coupled with presence of key players that are involved in research and innovation of novel gene detection methods is expected to drive the gene detection market in North America. For example, in 2020, FDA approved FoundationOne Liquid CDx, a gene detection test developed by Foundation Medicine Inc., which is based on liquid biopsy NGS.

Key players in the gene detection market include 

• Thermo Fisher Scientific Inc.
• Illumina, Inc.
• Agilent Technologies, Inc.
• Bio Rad Laboratories, Inc.
• Qiagen N.V.
• Roche Diagnostics (F. Hoffmann La Roche Ltd.)
• PerkinElmer, Inc.
• Becton, Dickinson and Company (BD)
• Danaher Corporation
• Merck KGaA
• GE Healthcare
• Abbott Laboratories
• Luminex Corporation
• Pacific Biosciences of California, Inc.
• Oxford Nanopore Technologies Ltd.

Product Type

• Instruments
• Kits & Reagents

Technology

• Polymerase Chain Reaction (PCR)
• Next Generation Sequencing (NGS)
• Micrarray
• FISH
• Others

Application

• Clinical Diagnostics
• Research
• Forensics
• Others

End user

• Hospitals & Clinics
• Diagnostic Laboratories
• Research Institutes
• Other

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa